131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
Mathematical models have predicted that targeted radiotherapy of neuroblastoma with metaiodobenzylguanidine (mIBG) is less likely to cure small rather than large micrometastases if 131I is the conjugated radionuclide. This study uses multicellular tumour spheroids as an in vitro model to test the hypothesis that smaller tumours of sub-millimetre dimensions are relatively resistant to 131I-mIBG. Spheroids of the human neuroblastoma cell line SK-N-BE(2c), either 250 microns or 400 microns diameter, were incubated with 131I-mIBG at concentrations of up to 6.0 MBq ml-1. Using both regrowth delay and spheroid 'cure' as endpoints, the greater vulnerability of larger spheroids was confirmed. From this in vitro result we conclude that when used in vivo 131I-mIBG may spare smaller micrometastases. Therefore, either a radionuclide such as 211At which emits a shorter path length radiation should be conjugated to mIBG, or targeted radiotherapy should be combined with a treatment such as total body irradiation, the efficacy of which is not reduced in smaller tumours.
Gaze
M N
MN
University of Glasgow Department of Radiation Oncology, Cancer Research Campaign Beatson Laboratories, Glasgow, UK.
Mairs
R J
RJ
Boyack
S M
SM
Wheldon
T E
TE
Barrett
A
A
D019797:3-Iodobenzylguanidine; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000627:therapeutic use*; D009447:Neuroblastoma / Q000473:pathology* / Q000532:radiotherapy*; D014407:Tumor Cells, Cultured
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine